英国非转移性前列腺癌局灶HIFU与冷冻治疗的肿瘤学结局:HEAT与ICE前瞻性登记研究3477例更新分析
基于英国HEAT与ICE前瞻性登记研究,纳入2004—2024年14个中心3477例接受初次局灶HIFU或冷冻治疗的非转移性前列腺癌患者,报告10年肿瘤控制结局。10年前列腺癌特异性死亡率为0.13%,全因死亡率12%,转移率3.3%,ADT使用率14%;意向性治疗分析下局部再治疗率33%、根治性治疗率30%。作者认为对精选患者,最多两次局灶消融可作为一线治疗选择。
要点
- 10年前列腺癌特异性死亡率为0.13%(95%CI 0.027-0.45%)。
- 意向性治疗分析10年局部再治疗率33%、根治性治疗率30%。
- 符合方案分析10年局部再治疗率13%、根治性治疗率8.9%。
核心结论
- 对精选的非转移性前列腺癌患者,最多两次局灶HIFU或冷冻治疗可考虑作为一线治疗选择,与根治性治疗并列。
- 未来研究应聚焦专用预后风险计算器、高危疾病局灶治疗的前瞻性评估以及局部复发检测与管理改进。
研究设计与样本
- 基于英国HEAT与ICE前瞻性维护登记研究的观察性分析,纳入2004—2024年14个英国中心3477例患者(HIFU 2897例,冷冻治疗580例)。
- 纳入标准为接受初次局灶HIFU或冷冻治疗的非转移性前列腺癌患者,随访至少6个月;干预包括最多两次局灶消融。
- 主要结局为前列腺癌特异性死亡,次要结局包括全因死亡、转移、局部再治疗、根治性治疗和ADT使用。
主要发现
- 48%、23%和25%的患者分别属于EAU 2025版有利中间危、不利中间危和高危疾病。
- 10年前列腺癌特异性死亡率为0.13%(95%CI 0.027-0.45%)。
- 10年全因死亡率为12%(95%CI 8.8-15%),转移率为3.3%(95%CI 2.1-4.9%)。
- 10年ADT使用率为14%(95%CI 11-17%)。
- 意向性治疗分析下10年局部再治疗率为33%(95%CI 30-37%),根治性治疗率为30%(95%CI 27-34%)。
关键数值与推荐
- 符合方案分析(post hoc per-protocol)中,对可能适合再次局灶消融但接受根治性治疗的患者在根治性治疗时进行删失;10年局部再治疗率为13%(95%CI 11-16%),根治性治疗率为8.9%(95%CI 6.9-11%)。
临床怎么用
- 局灶HIFU或冷冻治疗可作为精选非转移性前列腺癌患者的一线治疗选项之一,需与根治性治疗共同决策。
- 应向患者说明意向性治疗分析下10年局部再治疗率约33%、根治性治疗率约30%,以及符合方案分析下更低的再治疗率。
局限性
- 观察性研究设计是主要局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Long-term outcome data for focal therapy using high-intensity focused ultrasound (HIFU) or cryotherapy for nonmetastatic prostate cancer are needed. We report 10-yr cancer control outcomes. METHODS: Patients with nonmetastatic prostate cancer who underwent primary focal HIFU or cryotherapy and had at least 6 mo follow-up were identified from the UK HIFU Evaluation and Assessment of Treatment (HEAT) and International Cryotherapy Evaluation (ICE) prospectively maintained registries. The intervention included up to two focal ablative sessions. The primary outcome was cancer-specific mortality. Secondary outcomes were all-cause mortality, metastasis, local retreatment, radical treatment, and androgen-deprivation therapy (ADT) use. KEY FINDINGS AND LIMITATIONS: A total of 3477 patients (HIFU: n = 2897; cryotherapy: n = 580) were included from 14 UK centres (2004-2024). A total of 48%, 23%, and 25% had European Association of Urology (EAU) 2025-version favourable intermediate-, unfavourable-intermediate-, and high-risk disease, respectively. Ten-yr cancer-specific mortality was 0.13% (95% confidence interval [CI] = 0.027-0.45%). Ten-yr all-cause mortality and metastases were 12% (95% CI = 8.8-15%) and 3.3% (95% CI = 2.1-4.9%), respectively. Ten-yr ADT use was 14% (95% CI = 11-17%). Ten-yr local retreatment and radical treatment were 33% (95% CI = 30-37%) and 30% (95% CI = 27-34%), respectively, on an intention-to-treat basis. In a post hoc per-protocol analysis, undertaken to estimate outcomes under stricter adherence to the two focal ablative session protocol, patients who underwent radical treatment despite being potentially eligible for a further focal ablative session were censored at the time of radical treatment; 10-yr local retreatment and radical treatment were 13% (95% CI = 11-16%) and 8.9% (95% CI = 6.9-11%), respectively. The observational study design is the main limitation. CONCLUSIONS AND CLINICAL IMPLICATIONS: Focal therapy using up to two sessions of focal HIFU or cryotherapy could be considered as a first-line treatment for well-selected patients of nonmetastatic prostate cancer alongside radical treatment. Future research priorities should include the development of a dedicated prognostic risk calculator, further prospective assessment of focal therapy for high-risk disease, and improvements in the detection and management of locally recurrent disease.
引用
- Light A, Peters M, Gopalakrishnan A, et al. Oncological Outcomes Following Focal HIFU and Cryotherapy for Treatment of Nonmetastatic Prostate Cancer in the United Kingdom: An Updated Analysis of 3477 Patients from the Prospective HEAT and ICE Registries. Eur Urol. 2026. PMID: 42431756. doi:10.1016/j.eururo.2026.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。